Novel sst4-selective somatostatin (SRIF) agonists.: 3.: Analogues amenable to radiolabeling

被引:31
作者
Erchegyi, J
Waser, B
Schaer, JC
Cescato, R
Brazeau, JF
Rivier, J
Reubi, JC
机构
[1] Salk Inst Biol Studies, Clayton Fdn Labs Peptide Biol, La Jolla, CA 92037 USA
[2] Univ Bern, Inst Pathol, Div Cell Biol & Expt Canc Res, CH-3012 Bern, Switzerland
关键词
D O I
10.1021/jm030245x
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
After our discovery that H-c [Cys-Phe-Phe-DNal-Lys-Thr-Phe-Cys]-OH (ODN-8) had high affinity and marginal selectivity for human sst(3) (part 2 of this series: Erchegyi et al. J. Med. Chem., preceding paper in this issue)(11) and that H-c[Cys-Phe-Phe-DTrp-Lys-Thr-Phe-Cys]-OH (ODT-8, 3) had high affinity and marginal selectivity for human sst(4), that H-c[Cys-Phe-Tyr-D-threo-beta-Me2Nal-Lys-Thr-Phe-Cys]-OH had high affinity for all sst's except for sst(1), and that H-c[Cys-Phe-Tyr-L-threo-beta-Me2Nal-Lys-Thr-Phe-Cys]-OH had high affinity for sst(4) (IC50 = 2.1 nM), with more than 50-fold selectivity toward the other receptors (parts 1 and 2 of this series: Rivier et al. and Erchegyi et al. J Med. Chem., preceding papers in this issue), we found H-c[Cys-Phe-Phe-Trp-Lys-Thr-Phe-Cys]-OH (OLT-8,2), H-c[Cys-Phe-Phe-L-threo-beta-MeTrp-Lys-Thr-Phe-Cys]-OH (4) and H-c[Cys-Phe-Phe-D-threo-beta-MeTrp-Lys-Thr-Phe-Cys]-OH (5) to have very high affinity for sst(4) (IC50 = 0.7, 1.8, and 4.0 nM, respectively) and 5- to 10-fold selectivity versus the other sst's. From earlier work, we concluded that an L-amino acid at position 8 and a tyrosine or 4-aminophenylalanine substitution at position 7 may lead to high sst(4) selectivity. In fact, [Tyr(7)]-2 (6) and [Tyr(7)]-3 (7) show ca. 5-fold selectivity for sst(4), and [Aph(7)]-2 (8) and [Aph(7)]-3 (9) have high sst(4) affinity (IC50 = 1.2 and 0.88 nM, respectively) and selectivity, suggesting that indeed an L-residue at position 8 will direct selectivity toward sst(4) Unexpectedly, [Ala(7)]-2 (10) and [Ala(7)]-3 (11) have very high sst(4) affinity (IC50 = 0.84 and 0.98 nM, respectively) and selectivity (>600- and 200-fold, respectively). The combination of Tyr(2) and DTrp(8) in analogues 14 and 22 did not affect the affinity of the analogues for sst(4) (IC50 = 1.2 and 1.1 nM, respectively) but resulted in loss of selectivity, whereas the combination of Tyr(2) and LTrp(8) in H-Tyr-c[Cys-Phe-Aph-Trp-Lys-Thr-Phe-Cys]-OH (13) and H-Tyr-c[Cys-Phe-Ala-Trp-Lys-Thr-Phe-Cys]-OH-(19) retained high affinity (IC50 = 1.9 and 1.98 nM, respectively) and sst(4) selectivity (>50 and >250, respectively). Interestingly, the same substitutions at positions 2 and 7, with L-threo-beta-MeTrp at position 8, yielded a much less selective analogue (20). Carbamoylation of the N-terminus of most of these analogues resulted in slightly improved affinity, selectivity, or both. Other amino acid substitutions in this series, such as those with Amp (25, 26), Orn (27), or LAmp (29) at position 7, were also tolerated but with a 2- to Mold loss of affinity and concomitant loss of selectivity. Analogous peptides with a tyrosine at position 11 (31-36) were less selective than the corresponding peptides with a tyrosine at position 2. Several analogues in this series compared favorably with the non-peptide L-803,087 (37) in terms of affinity and selectivity. Analogues 8, 10, and 21 potently inhibited the forskolin-stimulated cAMP production in sst(4)-transfected cells, therefore acting as full agonists. Cold monoiodination of 19 yielded 21, with retention of high sst(4) selectivity and affinity (IC50 = 3.5 nM). (125)Iodinated 19 selectively binds to sst(4)-transfected cells but not to sst(1-3)- or sst(5)-transfected cells. Binding in sst(4)-transfected cells was completely displaced by SRIF-28 or the sst(4)-selective L-803,087.
引用
收藏
页码:5597 / 5605
页数:9
相关论文
共 45 条
[21]  
Panetta Rosemarie, 1995, Life Sciences, V56, P333
[22]   Somatostatin and its receptor family [J].
Patel, YC .
FRONTIERS IN NEUROENDOCRINOLOGY, 1999, 20 (03) :157-198
[23]  
PATEL YC, 1994, J BIOL CHEM, V269, P1506
[24]   A selective analog for the somatostatin sst1-receptor subtype expressed by human tumors [J].
Reubi, JC ;
Schaer, JC ;
Waser, B ;
Hoeger, C ;
Rivier, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 345 (01) :103-110
[25]   Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use [J].
Reubi, JC ;
Schär, JC ;
Waser, B ;
Wenger, S ;
Heppeler, A ;
Schmitt, JS ;
Mäcke, HR .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2000, 27 (03) :273-282
[26]   SST3-selective potent peptidic somatostatin receptor antagonists [J].
Reubi, JC ;
Schaer, JC ;
Wenger, S ;
Hoeger, C ;
Erchegyi, J ;
Waser, B ;
Rivier, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (25) :13973-13978
[27]   A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors [J].
Reubi, JC ;
Eisenwiener, KP ;
Rink, H ;
Waser, B ;
Mäcke, HR .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 456 (1-3) :45-49
[28]  
REUBI JC, 1995, J NUCL MED, V36, P1846
[29]   Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands [J].
Reubi, JC ;
Waser, B ;
Schaer, JC ;
Laissue, JA .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (07) :836-846
[30]   Novel sst4-selective soniatostatin (SRIF) agonists.: 1.: Lead identification using a betide scan [J].
Rivier, J ;
Erchegyi, J ;
Hoeger, C ;
Miller, C ;
Low, W ;
Wenger, S ;
Waser, B ;
Schaer, JC ;
Reubi, JC .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (26) :5579-5586